MX2011012625A - Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1). - Google Patents

Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1).

Info

Publication number
MX2011012625A
MX2011012625A MX2011012625A MX2011012625A MX2011012625A MX 2011012625 A MX2011012625 A MX 2011012625A MX 2011012625 A MX2011012625 A MX 2011012625A MX 2011012625 A MX2011012625 A MX 2011012625A MX 2011012625 A MX2011012625 A MX 2011012625A
Authority
MX
Mexico
Prior art keywords
muc1
antagonists
inflammation
inhibition
mucl
Prior art date
Application number
MX2011012625A
Other languages
English (en)
Spanish (es)
Inventor
Donald W Kufe
Surender Kharbanda
Original Assignee
Dana Faber Cancer Inst Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dana Faber Cancer Inst Inc filed Critical Dana Faber Cancer Inst Inc
Publication of MX2011012625A publication Critical patent/MX2011012625A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1735—Mucins, e.g. human intestinal mucin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4727—Mucins, e.g. human intestinal mucin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MX2011012625A 2009-05-27 2010-05-27 Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1). MX2011012625A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18153009P 2009-05-27 2009-05-27
US25373009P 2009-10-21 2009-10-21
US30399710P 2010-02-12 2010-02-12
PCT/US2010/036436 WO2010138740A1 (en) 2009-05-27 2010-05-27 Inhibition 0f inflammation using antagonists of muc1

Publications (1)

Publication Number Publication Date
MX2011012625A true MX2011012625A (es) 2012-04-20

Family

ID=43223089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012625A MX2011012625A (es) 2009-05-27 2010-05-27 Inhibicion de la inflamacion usando los antagonistas de mucina 1 (muc1).

Country Status (9)

Country Link
US (2) US8614186B2 (enExample)
EP (1) EP2435062A4 (enExample)
JP (1) JP5702371B2 (enExample)
CN (1) CN102665748A (enExample)
AU (1) AU2010253834B2 (enExample)
CA (1) CA2763327C (enExample)
IL (1) IL216612A0 (enExample)
MX (1) MX2011012625A (enExample)
WO (1) WO2010138740A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8524669B2 (en) 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
WO2011100688A1 (en) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
US20130101664A1 (en) 2011-08-18 2013-04-25 Donald W. Kufe Muc1 ligand traps for use in treating cancers
US9044421B2 (en) 2012-03-28 2015-06-02 Genus Oncology, Llc Treating MUC1-expressing cancers with combination therapies
US20150087598A1 (en) * 2012-05-11 2015-03-26 Dana-Farber Cancer Institute, Inc. Treating muc1-expressing cancers with helicase inhibitors
CN103848890B (zh) * 2012-11-30 2015-09-09 北京市结核病胸部肿瘤研究所 Muc1自身抗体识别的抗原多肽
WO2014164395A1 (en) 2013-03-11 2014-10-09 Dana-Farber Cancer Institute, Inc. Combination anti-estrogen receptor cancer therapy using muc1 peptides and chemotherapeutics
US10507227B2 (en) 2014-04-15 2019-12-17 The Hospital For Sick Children Cationic antimicrobial peptides
CN107074752B (zh) * 2014-07-02 2021-10-26 英费列特斯生命科学公司 苯亚甲基胍衍生物在治疗蛋白质构象紊乱方面的治疗用途
CA2999711A1 (en) 2014-09-26 2016-03-31 Rajendra Sahai Bhatnagar Inhibitors of nf kappa-b activity for treatment of diseases and disorders
EP3682246A1 (en) * 2017-09-13 2020-07-22 B.R.A.H.M.S GmbH Method for guidance of fluid therapy based on proadrenomedullin
CN107952069A (zh) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 重组疫苗及其应用
JP2022536289A (ja) * 2019-06-06 2022-08-15 ザ・ユニバーシティ・オブ・シドニー 抗炎症剤
CN117929754B (zh) * 2024-01-25 2025-02-11 广州医科大学附属第一医院（广州呼吸中心） Muc1-c段在肺动脉高压预防或治疗药物制备中的应用
WO2025217515A2 (en) * 2024-04-12 2025-10-16 Dana-Farber Cancer Institute, Inc. Identification of muc1-c as a target for the treatment of squamous cell carcinomas
WO2025231266A1 (en) * 2024-05-01 2025-11-06 Emory University Use of muc1 mimetic peptide inhibitors for inhibition of mucus secretion
CN119236051B (zh) * 2024-09-29 2025-12-19 北京大学 Muc1抑制剂在制备预防、治疗细菌感染药物中的应用

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5595756A (en) 1993-12-22 1997-01-21 Inex Pharmaceuticals Corporation Liposomal compositions for enhanced retention of bioactive agents
US5912232A (en) 1994-09-23 1999-06-15 Board Of Regents Of The University Of Nebraska Anti-inflammatory polypeptide antagonists of human I1-8
US6548643B1 (en) * 1994-11-16 2003-04-15 Austin Research Institute Antigen carbohydrate compounds and their use in immunotherapy
NO961031D0 (no) 1996-03-13 1996-03-13 Det Norske Radiumshospital Tum Fremgangsmåte til å drepe uönskede målceller
US20020044943A1 (en) 1997-09-10 2002-04-18 Longenecker B. Michael MUC-1 as an immunosuppressive therapeutic agent for the treatment of inflammatory and autoimmune conditions
WO2000034468A2 (en) * 1998-12-11 2000-06-15 Biomira Inc. Muc-1 antagonists and methods of treating immune disorders
JP2003510094A (ja) * 1999-09-08 2003-03-18 トランジェーヌ、ソシエテ、アノニム Ｍｕｃ−１由来のペプチド
JP2003533181A (ja) 2000-02-01 2003-11-11 ジ・オースティン・リサーチ・インスティテュート ムチン−１誘導抗原および免疫療法におけるその使用
AU9263101A (en) * 2000-09-11 2002-03-26 Donald W Kufe Muc1 extracellular domain and cancer treatment compositions and methods derived therefrom
AU2001289079A1 (en) * 2000-09-13 2002-03-26 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
EP1958642A1 (en) 2000-12-22 2008-08-20 Dana-Farber Cancer Institute Regulation of cell growth by MUC1
AU2002303390A1 (en) * 2001-04-18 2002-11-05 Dana-Farber Cancer Institute, Inc. Induction of apoptosis by cellular stress
US7247297B2 (en) * 2001-09-14 2007-07-24 The University Of Chicago Use of DF3/MUC1 regulated expression in gene therapy
WO2003034984A2 (en) * 2001-10-19 2003-05-01 Genentech, Inc. Compositions and methods for the diagnosis and treatment of inflammatory bowel disorders
US7696306B2 (en) * 2003-07-11 2010-04-13 Board of Agents of the University of Nebraska Compositions and methods for preventing or treating cancer
WO2005042573A1 (en) * 2003-10-24 2005-05-12 Dana-Farber Cancer Institute, Inc. Modulation of the interaction of muc1 with muc1 ligands
EP1538164A1 (en) * 2003-12-04 2005-06-08 Vectron Therapeutics AG RGD targeting moiety its production and use
CA2554537A1 (en) 2004-02-17 2005-09-01 Cancervax Corporation Method and composition for angiogenesis inhibition
US20070202134A1 (en) * 2004-02-23 2007-08-30 Kufe Donald W Muc1 Antagonist Enhancement of Death Receptor Ligand-Induced Apoptosis
WO2005101021A1 (en) 2004-04-13 2005-10-27 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with g protein-coupled adrenergic alpha-1d-receptor (adra1d)
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
JP2008537095A (ja) * 2005-02-15 2008-09-11 ダナ−ファーバー キャンサー インスティテュート インク． Ｍｕｃ１活性の調節
EP1868629B1 (en) * 2005-04-15 2014-10-22 Arizona Biomedical Research Commission Therapeutic fusion peptides for the treatment of metastatic cancer
US7612181B2 (en) * 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
US8017315B2 (en) * 2005-08-22 2011-09-13 Dana Farber Cancer Institute, Inc. Mitochondrial localization of MUC1
GB0519303D0 (en) 2005-09-21 2005-11-02 Oxford Biomedica Ltd Chemo-immunotherapy method
WO2008097840A2 (en) * 2007-02-02 2008-08-14 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of muc1 by hsf1 and stat3
US7871784B2 (en) * 2007-02-02 2011-01-18 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to the regulation of apoptosis by MUC1 and BH3-containing proapoptotic proteins
US8012695B2 (en) * 2007-02-14 2011-09-06 Dana-Farber Cancer Institute, Inc. Methods and compositions relating to promoter regulation by MUC1 and KLF proteins
JP5631201B2 (ja) * 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
US8524669B2 (en) * 2008-10-17 2013-09-03 Dana-Farber Cancer Institute, Inc. MUC-1 cytoplasmic domain peptides as inhibitors of cancer
WO2011100688A1 (en) * 2010-02-12 2011-08-18 Dana-Farber Cancer Institute, Inc. Improved antagonists of muc1
WO2011115819A2 (en) * 2010-03-15 2011-09-22 Genus Oncology, Llc Small molecule inhibitors of muc1 and methods of identifying the same

Also Published As

Publication number Publication date
CN102665748A (zh) 2012-09-12
JP5702371B2 (ja) 2015-04-15
IL216612A0 (en) 2012-02-29
EP2435062A1 (en) 2012-04-04
EP2435062A4 (en) 2013-01-02
US20140187494A1 (en) 2014-07-03
CA2763327A1 (en) 2010-12-02
AU2010253834A1 (en) 2011-12-08
WO2010138740A1 (en) 2010-12-02
US20110015138A1 (en) 2011-01-20
AU2010253834B2 (en) 2013-12-19
CA2763327C (en) 2019-04-02
US9096687B2 (en) 2015-08-04
US8614186B2 (en) 2013-12-24
JP2012528191A (ja) 2012-11-12

Similar Documents

Publication Publication Date Title
GB201017345D0 (en) Receptor antagonists
UA106900C2 (uk) Агоністичний dr5-зв'язувальний поліпептид
TN2011000639A1 (en) Compounds which selectively modulate the cb2 receptor
EP3725811A3 (en) Compositions for inhibiting masp-2 dependent complement activation
WO2014026136A3 (en) Protease-resistant systems for polypeptide display and methods of making and using thereof
SG11202000353QA (en) Emergency voice service support indications
MX339584B (es) Inhibidores de pi3 cinasa y usos de los mismos.
TW201144300A (en) Tetrazole compounds which selectively modulate the CB2 receptor
GB2566469B (en) Cache line statuses
MX2011014019A (es) Derivados de diazahomoadamantano y sus metodos de uso.
BRPI0906062A2 (pt) Inibidores de sinalização de brassinosteróides
EA201170640A1 (ru) Дизамещенные фталазины-антагонисты сигнального пути hedgehog
SG11202003678XA (en) Time based redundancy version determination for grant-free signaling
PH12013501904A1 (en) Pyridopyrazine derivatives and their use
GB2482817A (en) Novel use
MX2015017035A (es) Inhibidor de la señalizacion de cd40 y un compuesto adicional, en donde el compuesto adicional es un acido labil, un derivado de acido labil, un agonista del receptor tgr5, un agonista del fxr o una combinacion de los mismos, para el tratamiento de inflamacion cronica, y la prevencion de cancer gastrointestinal o fibrosis.
IN2014KN02993A (enExample)
IN2014DN07984A (enExample)
MX2010007669A (es) Metodos para inhibir la angiogenesis utilizando antagonistas de egfl8.
MX364912B (es) Antagonistas / agonistas inversos del receptor canabinoide.
MX2013010891A (es) Inhibidores de actividad inhibitoria de melanoma (mia) para detectar, prevenir y curar vitiligo.
IN2014CN00312A (enExample)
CA3013532A1 (en) Liraglutide in cardiovascular conditions
GB2560300B (en) Arc splitter plate
ECSP13012679A (es) Composiciones farmacéuticas que comprenden alisporivir

Legal Events

Date Code Title Description
FA Abandonment or withdrawal